Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

The expanding success of T cell-engaging bispecific antibodies

Nature Cancer volume 4, pages 1054–1055 (2023)Cite this article

Subjects

T cell-based immunotherapies have revolutionized cancer treatment, and strategies to redirect T cells to recognize cancer cells are being investigated both preclinically and clinically. Bispecific T cell-engagers are antibodies that simultaneously bind to an antigen on tumor cells and a surface molecule on T cells. They have shown impressive activity in B cell malignancies and are being explored in many other cancer entities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nathan, P. et al. N. Engl. J. Med. 385, 1196–1206 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Göbeler, M. E. et al. J. Clin. Oncol. 34, 974–977 (2016).

    Google Scholar 

  3. Gökbuget, N. Blood 131, 1522–1531 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kantarjian, H. et al. N. Engl. J. Med. 376, 836–847 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Budde, L. E. et al. Lancet Oncol. 23, 1055–1065 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Dickinson, M. J. et al. N. Engl. J. Med. 387, 2220–2231 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Thieblemont, C. et al. J. Clin. Oncol. 41, 2238–2247 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Chari, A. et al. N. Engl. J. Med. 387, 2232–2244 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Litzow, M. R. et al. Blood 140 (suppl. 2), LBA-1 (2022).

  11. Foà, R. et al. N. Engl. J. Med. 383, 1613–2163 (2020).

    Article  PubMed  Google Scholar 

  12. Hummel, H. D. et al. Immunother. 13, 125–141 (2021).

    Article  CAS  Google Scholar 

  13. Paz-Ares, L. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.22.02823 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Banaszek, A. Nat. Commun. 26, 5387 (2019).

    Article  Google Scholar 

  15. Goebeler, M. E. & Bargou, R. C. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center Mainfranken and Bavarian Cancer Research Center (BZKF), University Hospital Würzburg, Würzburg, Germany

    Ralf C. Bargou

Authors
  1. Ralf C. Bargou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralf C. Bargou.

Ethics declarations

Competing interests

R.C.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex and Gemoab.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bargou, R.C. The expanding success of T cell-engaging bispecific antibodies. Nat Cancer 4, 1054–1055 (2023). https://doi.org/10.1038/s43018-023-00586-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00586-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing